In acute myeloid leukemia (AML), newer options, such as a FLT3 inhibitor for relapsing-remitting disease and several therapies for patients who are ineligible for intensive chemotherapy, are pushing out old standards, according to data recently presented at the 2020 virtual annual meetings of the American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA). After decades of little progress, the options in AML are evolving quickly.
ADMIRAL Trial: Long-Term Survivors
New